US20130323319A1 - Modified immune-modulating particles - Google Patents

Modified immune-modulating particles Download PDF

Info

Publication number
US20130323319A1
US20130323319A1 US13/884,817 US201113884817A US2013323319A1 US 20130323319 A1 US20130323319 A1 US 20130323319A1 US 201113884817 A US201113884817 A US 201113884817A US 2013323319 A1 US2013323319 A1 US 2013323319A1
Authority
US
United States
Prior art keywords
particles
carboxylated
mice
infection
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/884,817
Other languages
English (en)
Inventor
Daniel R. GETTS
Rachael Terry
Nicholas King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncour Pharma Inc
Original Assignee
GETTS CONSULTING AND PROJECT MANAGEMENT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GETTS CONSULTING AND PROJECT MANAGEMENT filed Critical GETTS CONSULTING AND PROJECT MANAGEMENT
Priority to US13/884,817 priority Critical patent/US20130323319A1/en
Assigned to GETTS CONSULTING AND PROJECT MANAGEMENT reassignment GETTS CONSULTING AND PROJECT MANAGEMENT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KING, NICHOLAS, TERRY, RACHAEL, GETTS, DANIEL
Assigned to GETTS CONSULTING AND PROJECT MANAGEMENT reassignment GETTS CONSULTING AND PROJECT MANAGEMENT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KING, NICHOLAS, TERRY, RACHEL, GETTS, DANIEL
Publication of US20130323319A1 publication Critical patent/US20130323319A1/en
Assigned to COUR PHARMACEUTICALS DEVELOPMENT COMPANY reassignment COUR PHARMACEUTICALS DEVELOPMENT COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GETTS CONSULTING AND PROJECT MANAGEMENT
Assigned to ONCOUR PHARMA, INC. reassignment ONCOUR PHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COUR PHARMACEUTICALS DEVELOPMENT CO., INC.
Assigned to COUR PHARMACEUTICALS DEVELOPMENT CO., INC. reassignment COUR PHARMACEUTICALS DEVELOPMENT CO., INC. CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 35092 FRAME: 859. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: GETTS CONSULTING AND PROJECT MANAGEMENT
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Definitions

  • Inflammatory diseases and disorders are conditions in which an abnormal or otherwise deregulated inflammatory response contributes to the etiology or severity of disease.
  • autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and diabetes
  • infectious diseases such as tuberculosis and various forms of meningitis and encephalitis including West Nile Virus encephalitis and other disorders include atherosclerosis and ischemic reperfusion.
  • mononuclear cell infiltration at a site of tissue injury or other insult.
  • mononuclear cells that have been observed in these infiltrations include lymphocytes, especially T lymphocytes, and cells of the mononuclear phagocyte system (MPS cells) such as monocytes, macrophages, dendritic cells, microglial cells and others.
  • lymphocytes especially T lymphocytes
  • MPS cells mononuclear phagocyte system
  • CD4 + T cells are known to play a central role in the pathologic autoimmune response.
  • dendritic cells and other MPS cells may be responsible for activation of CD4 + T cells.
  • MPS cells could also contribute to inflammation through phagocytosis although in at least some inflammatory diseases it is not clear whether such cells would be capable of this in the absence of CD4 + T cells.
  • Peripheral blood monocytes may be classified into one of two groups according to the expression or not of certain cell surface molecules.
  • human “resident monocytes” or “mature monocytes” are understood to have a CD14 lo CD16 + phenotype (the mouse counterpart is CX 3 CR1 hi CCR2 ⁇ Gr1 ⁇ ).
  • Another group of cells the “inflammatory monocytes” or “immature monocytes” are understood to have a CD14 + CD16 ⁇ phenotype (the mouse counterpart is CX 3 CR1 lo CCR2 + Gr1 + ).
  • peptide induced cell coupled tolerance involved collection, separation and treatment of peripheral blood cells with disease specific autoantigens and the ethylene carbodimide (ECDI) coupling reagent under sterile conditions, and subsequent re-infusion into the donor/patient.
  • ECDI ethylene carbodimide
  • Antigen-specific tolerance is generally not ideal because specific antigens/eptitopes are generally not known in human diseases.
  • antigens can vary from subject to subject in order for an antigen specific approach to be effective, therefore it would be necessary to determine which antigens each individual patient would recognize, or it would require coupling a library of possible peptides to the particles prior to administration. The synthesis and individual coupling of these peptides is both time consuming and expensive. Therefore, a need exists for a therapy which solves both of these problems thereby eliminating the need to for a source of tissue matched cells and at the same time eliminating the need to synthesize and couple large panels of peptides.
  • the current invention involves the surprising finding that modified particles alone, that is, without a peptide coupled thereto, are effective in ameliorating the inflammatory immune response in patients in need thereof. Surprisingly, all that is necessary to dampen an inflammatory immune response, and treat inflammatory disease is the administration of carboxylated particles, without the need for coupling peptide(s) thereto.
  • the current invention provides a pharmaceutical composition comprising carboxylated particles.
  • the carboxylated particles are free from attached peptide or antigenic moieties.
  • the carboxylated particles are polystyrene particles.
  • the carboxylated particles are diamond particles.
  • the carboxylated particles are poly(lactic-co-glycolic acid) (PLGA) particles.
  • the pharmaceutical composition containing the carboxylated particles induces immune tolerance when administered to a subject in need thereof. In a further embodiment, the pharmaceutical composition containing the carboxylated particles ameliorates an inflammatory immune response when administered to a subject in need thereof.
  • the carboxylated particles comprising the pharmaceutical formulation of the current invention have a diameter of about 0.1 ⁇ m to about 10 ⁇ m. In a further embodiment, the carboxylated particles have a diameter of about 0.3 ⁇ m to about 5 ⁇ m. In yet a further embodiment the carboxylated particles have a diameter of about 0.5 ⁇ m to about 3 ⁇ m. In still a further embodiment, the carboxylated particles have a diameter of about 0.5 ⁇ m.
  • the current invention provides a method of reducing the duration or severity of an inflammatory immune response in a subject comprising administering to the subject a pharmaceutical composition comprising carboxylated particles.
  • the carboxylated particles are free from attached peptide or antigenic moieties.
  • the carboxylated particles are polystyrene particles.
  • the carboxylated particles are diamond particles.
  • the carboxylated particles are poly(lactic-co-glycolic acid) (PLGA) particles.
  • the method of the invention induces immune tolerance when administered to a subject in need thereof. In a further embodiment, the method ameliorates an inflammatory immune response when administered to a subject in need thereof.
  • the method of the invention utilizes carboxylated particles comprising those having a diameter of about 0.1 ⁇ m to about 10 ⁇ m.
  • the carboxylated particles have a diameter of about 0.3 ⁇ m to about 5 ⁇ m.
  • the carboxylated particles have a diameter of about 0.5 ⁇ m to about 3 ⁇ m.
  • the carboxylated particles have a diameter of about 0.5 ⁇ m.
  • the subject has an autoimmune disorder.
  • the autoimmune disorder is multiple sclerosis, scleroderma, type-I diabetes, rheumatoid arthritis, thyroiditis, systemic lupus erythmatosis, Reynauud's syndrome, Sjorgen's syndrome, autoimmune uveitis, autoimmune myocarditis, or Crohn's disease.
  • the autoimmune disease is multiple sclerosis
  • the subject has an allergic disorder.
  • the allergic disorder is eczema, asthma, allergic rhinitis or skin hypersensitivity.
  • the subject is a transplant recipient.
  • the subject has suffered a cardiac infarction.
  • the patient has ischemic reperfusion.
  • the patient has atherosclerosis.
  • the method includes administering the carboxylated particles by any suitable means.
  • the composition is administered orally, nasally, intravenously, intramuscularly, ocularly, transdermally, or subcutaneously.
  • the carboxylated particles are administered nasally.
  • the particles are administered intravenously.
  • the current invention provides a method of treating a bacterial or viral infection in a subject comprising administering to the subject a pharmaceutical composition comprising carboxylated particles.
  • the carboxylated particles are free from attached peptide or antigenic moieties.
  • the carboxylated particles are polystyrene particles.
  • the carboxylated particles are diamond particles.
  • the carboxylated particles are poly(lactic-co-glycolic acid) (PLGA) particles.
  • the method of the invention induces immune tolerance when administered to a subject with a bacterial or viral infection. In a further embodiment, the method ameliorates or dampens an inflammatory immune response when administered to a subject with a bacterial or viral infection.
  • the methods of treating a bacterial or viral infection of the invention utilizes carboxylated particles comprising having a diameter of about 0.1 ⁇ m to about 10 ⁇ m.
  • the carboxylated particles have a diameter of about 0.3 ⁇ m to about 5 ⁇ m.
  • the carboxylated particles have a diameter of about 0.5 ⁇ m to about 3 ⁇ m.
  • the carboxylated particles have a diameter of about 0.5 ⁇ m.
  • the subject has a viral infection.
  • the viral infection is a herpes virus infection, a hepatitis virus infection, a west nile virus infection, a flavivirus, an influenza infection, a rhinovirus infection, a papillomavirus infection, a or parainfluenza virus infection.
  • the viral infection infects the central nervous system of said subject.
  • the viral infection causes viral encephalitis or viral meningitis.
  • the subject has a bacterial infection.
  • the bacterial infection infects the central nervous system of said subject.
  • the bacterial infection causes sepsis bacterial encephalitis or bacterial meningitis.
  • FIG. 1 shows (A) the percent survival of mice after high dose or low dose infection with WNV; (B) weight loss associated with high dose infection of mice with WNV; (C) the viral titers in the brain of mice that succumb to infection; (D) weight loss in mice infected with high and low dose WNV through days 0-7 post infection; (E) the viral titers in the brains of mice infected with high and low dose WNV at day 7 post infection and the correlation between percentage of weight loss on day 7 and viral titer; (F) the correlation between percentage weight loss and the presence of CD45 + leukocytes in the brain of mice at 7 days post infection with high and low dose WNV; (G) the correlation between viral titer in the brain and the presence of CD45 + leukocytes in the brain of mice at 7 days post infection with high and low dose WNV; (H) the correlation between percentage weight loss and the presence of CD45 hi macrophages in the brain of mice at 7 days post infection with high and low dose WNV.
  • FIG. 2 shows the correlation between percentage of weight loss and the presence of (A) CD45 int CD11b + immigrant microglia; (C) CD3 + T cells; (D) CD11b hi Ly6G + neutrophils and (E) NK1.1 + CD11b lo/ ⁇ natural killer cells while the numbers of CD45 lo resident microglia (B) remained unchanged after 7 days post infection with high dose or low dose WNV; (F) shows the correlation between weight loss and virus titer in the brain at the time of sacrifice of mice infected with low dose WNV; (G) shows the correlation of leukocyte infiltration and percentage weight loss in mice infected with low dose WNV and (H) shows that there was no correlation between virus titer and leukocyte infiltration after low dose WNV infection.
  • FIG. 3 shows the long term survival of mice treated with carboxylated polystyrene beads in PBS at day 6 after infection with high dose WNV;
  • B shows that treating low dose WNV-infected mice with carboxylated polystyrene beads beginning at day 6 post infection is ineffective at prolonging survival of mice;
  • C shows that treating low dose WNV-infected mice with carboxylated polystyrene beads beginning at day 6 post infection is ineffective at preventing weight loss in mice compared to control mice;
  • D shows that treatment of low dose WNV-infected mice is effective at prolonging survival of mice when the beads are administered upon weight loss in the mice.
  • E-G shows weight loss recorded in these mice up to 20 days pi.
  • FIG. 4 (A-D) are examples of treating low dose WNV-infected mice with carboxylated polystyrene beads upon weight loss in the mice the mice in (A-B) only require bead treatment for 5 days and weight remains stable and they go on to survive without further bead treatment, whereas the mice in (C-D) begin to lose weight again when bead treatment is ceased after 5 days, so treatment resumes until weight restabalizes
  • E shows the infiltration of CD45 + CD11b + macrophages into the brains of low dose WNV-infected mice at 9 days post infection, that either lost weight or did not lose weight and were treated with either PBS or carboxylated beads at day 8 post infection
  • (F) is a graphical representation of the types of cells found infiltrating the brain of WNV-infected mice at 9 days post infection, that either lost weight or did not lose weight and were treated with either PBS or carboxylated beads at day 8 post infection.
  • FIG. 5 shows (A) the difference in survival of mice treated with carboxylated polystyrene beads, naked polystyrene beads or PBS after low dose infection with WNV; (B) shows the difference in percent weight loss in mice treated with carboxylated beads, naked beads or PBS after low dose infection with WNV; (C,D) shows the difference in percent weight loss between carboxylated bead treatment and naked bead treatment in mice after low dose infection with WNV; (E,O) shows the localization of FITC-conjugated carboxylated beads or naked beads on day 7 in mice infected with high dose WNV on day 0 and FITC-carboxylated beads, FITC-naked beads or PBS on day 6.
  • (E-G) are blood from 3 separate PBS-treated mice
  • (H-J) are blood from 3 separate naked polystyrene bead-treated mice
  • (L-N) are blood from 3 separate carboxylated polystyrene bead-treated mice, showing that more of the plain beads remain in the blood than carboxylated beads.
  • FIG. 6 shows (A-C) the lack of infiltration of FITC-conjugated polystyrene beads in the brains of mice infected and treated as in FIG. E-O; (D-E) shows the reduction in infiltration of various leukocytes, macrophages and microglia into the brains of WNV-infected mice treated with carboxylated polystyrene beads or naked polystyrene beads as in FIG. 5 (E-O).
  • FIG. 7 shows (A) the association of FITC-conjugated polystyrene carboxylated beads and FITC-conjugated naked polystyrene beads in the spleen with CD45 + leukocytes (A,B,F) within CD11b + (C,G), CD11c + (D,H) Ly6c + (E,I) cells; (J-R) shows the types of cells that take up FITC-conjugated carboxylated beads and FITC-conjugated naked beads
  • FIG. 8 shows the ability of FITC-conjugated polystyrene carboxylated beads or FITC-conjugated naked polystyrene beads to be taken up by and increase the numbers of CD11b + CD11c ⁇ monocytes (A) and CD11b + CD11c ⁇ (B) or CD11b ⁇ CD11c + (C) dendritic cells in the spleen after infection with high dose WNV.
  • FIG. 9 shows (A-D) the ability of FITC-conjugated carboxylated polystyrene beads or FITC conjugated naked polystyrene beads to be taken up by and increase the numbers of CD19 + B cell and CD3 + T cell subsets in the spleen after infection with high dose WNV.
  • FIG. 10 shows (A-L) the ability of FITC-conjugated carboxylated polystyrene beads or FITC conjugated naked polystyrene beads to be taken up by CD11b + (C,G), CD11c + (D,H), and Ly6c + (E,I) cells, specifically, within CD11b + CD11c ⁇ monocytes (J) and CD11b + CD11c + (K) or CD11b ⁇ CD11c + (L) dendritic cells, in the liver after infection with high dose WNV.
  • FIG. 11 shows (A-G) the ability of FITC-conjugated carboxylated polystyrene beads or FITC conjugated naked polystyrene beads to be taken up by CD11b + , (C,F), CD11c + and Ly6C + (D,G) cells, in the bone marrow after infection with high dose WNV.
  • FIG. 12 shows (A) the percent survival of low dose WNV-infected mice treated with high dose or low dose carboxylated polystyrene beads of different sizes; (B) shows the percent survival of low dose WNV-infect mice treated with FITC-conjugated carboxylated beads, naked FITC-conjugated beads, carboxylated PLGA spheres or naked PLGA spheres; (C) shows the infiltration/activation of various monocyte populations in the brain of mice infected with low dose WNV and treated with carboxylated FITC-beads, carboxylated-FITC PLGA spheres, or carboxylated nanodiamonds.
  • FIG. 13 shows (A) the percent survival and (B) weight loss in wild-type and T cell deficient mice infected with high or low dose WNV; (C) the correlation between weight loss and viral titers in the brains of wild-type and T cell deficient mice infected with high or low dose WNV; (D) weight loss (E) and immune cell infiltration into the brains of wild type and T cell deficient mice infected with high dose WNV at day 8 post infection; (F) percent survival (G) and weight loss of wild-type and T cell deficient mice infected with high or low dose WNV and treated with carboxylated beads or PBS upon significant weight loss.
  • the present inventors have surprisingly found that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles of a certain size, are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present inventors have also surprisingly found that these same carboxylated particles, when administered to subjects with active viral or bacterial infections, particularly those infecting the central nervous system prolong, lead to a dramatic decrease in symptoms of these infections and prolonged survival. These, particles, therefore, may be useful in the treatment of any disease or condition characterized by an excessive inflammatory immune response, such as autoimmune diseases, as well as in the treatment of bacterial and viral infections.
  • carboxylated particles such as carboxylated polystyrene, PLGA, or diamond particles of a certain size
  • Particle refers to any non-tissue derived minute composition of matter, it may be a sphere or sphere-like entity or bead.
  • the term “particle” and the term “bead” may be used interchangeably. Additionally, the term “particle” may be used to encompass beads and spheres.
  • Carboxylated particles or “carboxylated beads” or “carboxylated spheres” includes any particle that has been modified to contain a carboxyl group on its surface. In some embodiments the addition of the carboxyl group enhances phagocyte/monocyte uptake of the particles from circulation, for instance through the interaction with scavenger receptors such as MARCO.
  • Antigenic moiety refers to any moiety, for example a peptide, that is recognized by the host's immune system.
  • antigenic moieties include, but are not limited to, autoantigens and/or bacterial or viral proteins, peptides or components.
  • carboxylated beads themselves may be recognized by the immune system, the carboxylated beads with nothing more attached thereto are not considered an “antigenic moiety” for the purposes of the invention.
  • naked beads or “naked particles” or “naked spheres” as used herein refers to beads, particles or spheres that have not been carboxylated.
  • the particle may have any particle shape or conformation. However, in some embodiments it is preferred to use particles that are less likely to clump in vivo. Examples of particles within these embodiments are those that have a spherical shape.
  • each particle it is not necessary that each particle be uniform in size, although the particles must generally be of a size sufficient to trigger phagocytosis in an antigen presenting cell or other MPS cell.
  • the particles are microscopic or nanoscopic in size, in order to enhance solubility, avoid possible complications caused by aggregation in vivo and to facilitate pinocytosis.
  • Particle size can be a factor for uptake from the interstitial space into areas of lymphocyte maturation.
  • a particle having a diameter of from about 0.1 ⁇ m to about 10 ⁇ m is capable of triggering phagocytosis.
  • the particle has a diameter within these limits.
  • the particle has a diameter of about 0.3 ⁇ m to about 5 ⁇ m.
  • the particle has a diameter of about 0.5 ⁇ m to about 3 ⁇ m. In preferred embodiment the particle has a size of about 0.5 ⁇ m.
  • the particles in a composition need not be of uniform diameter.
  • a pharmaceutical formulation may contain a plurality of particles, some of which are about 0.5 ⁇ m, while others are about 1.0 ⁇ m. Any mixture of particle sizes within these given ranges will be useful.
  • the particle is non-metallic.
  • the particle may be formed from a polymer.
  • the particle is biodegradable in an individual.
  • the particles can be provided to an individual across multiple doses without there being an accumulation of particles in the individual. Examples of suitable particles include polystyrene particles, PLGA particles, and diamond particles.
  • the particle surface is composed of a material that minimizes non-specific or unwanted biological interactions. Interactions between the particle surface and the interstitium may be a factor that plays a role in lymphatic uptake.
  • the particle surface may be coated with a material to prevent or decrease non-specific interactions.
  • Steric stabilization by coating particles with hydrophilic layers such as poly(ethylene glycol) (PEG) and its copolymers such as PLURONICS (including copolymers of poly(ethylene glycol)-bl-poly(propylene glycol)-bl-poly(ethylene glycol)) may reduce the non-specific interactions with proteins of the interstitium as demonstrated by improved lymphatic uptake following subcutaneous injections.
  • PEG poly(ethylene glycol)
  • PLURONICS including copolymers of poly(ethylene glycol)-bl-poly(propylene glycol)-bl-poly(ethylene glycol)
  • Biodegradable polymers may be used to make all or some of the polymers and/or particles and/or layers. Biodegradable polymers may undergo degradation, for example, by a result of functional groups reacting with the water in the solution.
  • degradation refers to becoming soluble, either by reduction of molecular weight or by conversion of hydrophobic groups to hydrophilic groups. Polymers with ester groups are generally subject to spontaneous hydrolysis, e.g., polylactides and polyglycolides.
  • Particles of the present invention may also contain additional components.
  • carriers may have imaging agents incorporated or conjugated to the carrier.
  • An example of a carrier nanosphere having an imaging agent that is currently commercially available is the Kodak X-sight nanospheres.
  • Inorganic quantum-confined luminescent nanocrystals, known as quantum dots (QDs) have emerged as ideal donors in FRET applications: their high quantum yield and tunable size-dependent Stokes Shifts permit different sizes to emit from blue to infrared when excited at a single ultraviolet wavelength.
  • QDs quantum dots
  • Quantum dots such as hybrid organic/inorganic quantum dots based on a class of polymers known as dendrimers, may used in biological labeling, imaging, and optical biosensing systems. (Lemon, et al., J. Am. Chem. Soc. 2000, 122, 12886). Unlike the traditional synthesis of inorganic quantum dots, the synthesis of these hybrid quantum dot nanoparticles does not require high temperatures or highly toxic, unstable reagents. (Etienne, et al., Appl. Phys. Lett. 87, 181913, 2005).
  • Particles can be formed from a wide range of materials.
  • the particle is preferably composed of a material suitable for biological use.
  • particles may be composed of glass, silica, polyesters of hydroxy carboxylic acids, polyanhydrides of dicarboxylic acids, or copolymers of hydroxy carboxylic acids and dicarboxylic acids.
  • the carrier particles may be composed of polyesters of straight chain or branched, substituted or unsubstituted, saturated or unsaturated, linear or cross-linked, alkanyl, haloalkyl, thioalkyl, aminoalkyl, aryl, aralkyl, alkenyl, aralkenyl, heteroaryl, or alkoxy hydroxy acids, or polyanhydrides of straight chain or branched, substituted or unsubstituted, saturated or unsaturated, linear or cross-linked, alkanyl, haloalkyl, thioalkyl, aminoalkyl, aryl, aralkyl, alkenyl, aralkenyl, heteroaryl, or alkoxy dicarboxylic acids.
  • carrier particles can be quantum dots, or composed of quantum dots, such as quantum dot polystyrene particles (Joumaa et al. (2006) Langmuir 22: 1810-6).
  • Carrier particles including mixtures of ester and anhydride bonds e.g., copolymers of glycolic and sebacic acid may also be employed.
  • carrier particles may comprise materials including polyglycolic acid polymers (PGA), polylactic acid polymers (PLA), polysebacic acid polymers (PSA), poly(lactic-co-glycolic) acid copolymers (PLGA), [rho]oly(lactic-co-sebacic) acid copolymers (PLSA), poly(glycolic-co-sebacic) acid copolymers (PGSA), etc.
  • PGA polyglycolic acid polymers
  • PLA polylactic acid polymers
  • PSA polysebacic acid polymers
  • PLA poly(lactic-co-glycolic) acid copolymers
  • PLSA poly(lactic-co-glycolic) acid copolymers
  • PGSA poly(glycolic-co-sebacic) acid copolymers
  • biocompatible, biodegradable polymers useful in the present invention include polymers or copolymers of caprolactones, carbonates, amides, amino acids, orthoesters, acetals, cyanoacrylates and degradable urethanes, as well as copolymers of these with straight chain or branched, substituted or unsubstituted, alkanyl, haloalkyl, thioalkyl, aminoalkyl, alkenyl, or aromatic hydroxy- or di-carboxylic acids.
  • the biologically important amino acids with reactive side chain groups such as lysine, arginine, aspartic acid, glutamic acid, serine, threonine, tyrosine and cysteine, or their enantiomers, may be included in copolymers with any of the aforementioned materials to provide reactive groups for conjugating to antigen peptides and proteins or conjugating moieties.
  • Biodegradable materials suitable for the present invention include diamond, PLA, PGA, and PLGA polymers. Biocompatible but non-biodegradable materials may also be used in the carrier particles of the invention.
  • non-biodegradable polymers of acrylates, ethylene-vinyl acetates, acyl substituted cellulose acetates, non-degradable urethanes, styrenes, vinyl chlorides, vinyl fluorides, vinyl imidazoles, chlorosulphonated olefins, ethylene oxide, vinyl alcohols, TEFLON® (DuPont, Wilmington, Del.), and nylons may be employed.
  • Suitable beads which are currently available commercially include polystyrene beads such as FluoSpheres (Molecular Probes, Eugene, Oreg.).
  • Physical properties are also related to a nanoparticle's usefulness after uptake and retention in areas having immature lymphocytes. These include mechanical properties such as rigidity or rubberiness.
  • Some embodiments are based on a rubbery core, e.g., a polypropylene sulfide) (PPS) core with an overlayer, e.g., a hydrophilic overlayer, as in PEG, as in the PPS-PEG system recently developed and characterized for systemic (but not targeted or immune) delivery.
  • PPS polypropylene sulfide
  • the rubbery core is in contrast to a substantially rigid core as in a polystyrene or metal nanoparticle system.
  • the term rubbery refers to certain resilient materials besides natural or synthetic rubbers, with rubbery being a term familiar to those in the polymer arts.
  • cross-linked PPS can be used to form a hydrophobic rubbery core.
  • PPS is a polymer that degrades under oxidative conditions to polysulphoxide and finally polysulphone, transitioning from a hydrophobic rubber to a hydrophilic, water-soluble polymer.
  • Other sulphide polymers may be adapted for use, with the term sulphide polymer referring to a polymer with a sulphur in the backbone of the mer.
  • Other rubbery polymers that may be used are polyesters with glass transition temperature under hydrated conditions that is less than about 37° C.
  • a hydrophobic core can be advantageously used with a hydrophilic overlayer since the core and overlayer will tend not to mingle, so that the overlayer tends to sterically expand away from the core.
  • a core refers to a particle that has a layer on it.
  • a layer refers to a material covering at least a portion of the core.
  • a layer may be adsorbed or covalently bound.
  • a particle or core may be solid or hollow. Rubbery hydrophobic cores are advantageous over rigid hydrophobic cores, such as crystalline or glassy (as in the case of polystyrene) cores, in that higher loadings of hydrophobic drugs can be carried by the particles with the rubbery hydrophobic cores.
  • a hydrophilic material may have a solubility in water of at least 1 gram per liter when it is uncrosslinked. Steric stabilization of particles with hydrophilic polymers can improve uptake from the interstitium by reducing non-specific interactions; however, the particles' increased stealth nature can also reduce internalization by phagocytic cells in areas having immature lymphocytes. The challenge of balancing these competing features has been met, however, and this application documents the creation of nanoparticles for effective lymphatic delivery to DCs and other APCs in lymph nodes.
  • Some embodiments include a hydrophilic component, e.g., a layer of hydrophilic material.
  • hydrophilic materials are one or more of polyalkylene oxides, polyethylene oxides, polysaccharides, polyacrylic acids, and polyethers.
  • the molecular weight of polymers in a layer can be adjusted to provide a useful degree of steric hindrance in vivo, e.g., from about 1,000 to about 100,000 or even more; artisans will immediately appreciate that all the ranges and values within the explicitly stated ranges are contemplated, e.g., between 10,000 and 50,000.
  • the nanoparticles may incorporate functional groups for further reaction.
  • Functional groups for further reaction include electrophiles or nucleophiles; these are convenient for reacting with other molecules.
  • nucleophiles are primary amines, thiols, and hydroxyls.
  • electrophiles are succinimidyl esters, aldehydes, isocyanates, and maleimides.
  • the particles of the current invention can be given in any dose effective to dampen the inflammatory immune response in a subject in need thereof or to treat a bacterial or viral infection in a subject in need thereof.
  • about 10 2 to about 10 20 particles are provided to the individual.
  • between about 10 3 to about 10 15 particles are provided.
  • between about 10 6 to about 10 12 particles are provided.
  • between about 10 8 to about 10 10 particles are provided.
  • the preferred dose is 0.1% solids/ml.
  • a preferred dose is approximately 4 ⁇ 10 9 beads, for 0.05 ⁇ m beads, a preferred dose is approximately 4 ⁇ 10 12 beads, for 3 ⁇ m beads, a preferred dose is 2 ⁇ 10 7 beads.
  • any dose that is effective in treating the particular condition to be treated is encompassed by the current invention.
  • the invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions.
  • Substitution of a synthetic, biocompatible particle system to induce immune tolerance could lead to ease of manufacturing, broad availability of therapeutic agents, increase uniformity between samples, increase the number of potential treatment sites and dramatically reduce the potential for allergic responses to a carrier cell.
  • immune response includes T cell mediated and/or B cell mediated immune responses.
  • exemplary immune responses include T cell responses, e.g., cytokine production and cellular cytotoxicity.
  • immune response includes immune responses that are indirectly affected by T cell activation, e.g., antibody production (humoral responses) and activation of cytokine responsive cells, e.g., macrophages.
  • Immune cells involved in the immune response include lymphocytes, such as B cells and T cells (CD4 + , CD8 + , Th1 and Th2 cells); antigen presenting cells (e.g., professional antigen presenting cells such as dendritic cells, macrophages, B lymphocytes, Langerhans cells, and nonprofessional antigen presenting cells such as keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes); natural killer cells; myeloid cells, such as macrophages, eosinophils, mast cells, basophils, and granulocytes.
  • the modified particles of the present invention are effective to reduce inflammatory cell trafficking to the site of inflammation.
  • the term “anergy,” “tolerance,” or “antigen-specific tolerance” refers to insensitivity of T cells to T cell receptor-mediated stimulation. Such insensitivity is generally antigen-specific and persists after exposure to the antigenic peptide has ceased. For example, anergy in T cells is characterized by lack of cytokine production, e.g., IL-2. T-cell anergy occurs when T cells are exposed to antigen and receive a first signal (a T cell receptor or CD-3 mediated signal) in the absence of a second signal (a costimulatory signal).
  • a first signal a T cell receptor or CD-3 mediated signal
  • cytokines e.g., IL-2
  • T cell anergy can also be observed by the lack of IL-2 production by T lymphocytes as measured by ELISA or by a proliferation assay using an indicator cell line.
  • a reporter gene construct can be used.
  • anergic T cells fail to initiate DL-2 gene transcription induced by a heterologous promoter under the control of the 5′ IL-2 gene enhancer or by a multimer of the API sequence that can be found within the enhancer (Kang et al. 1992 Science. 257:1134).
  • immunological tolerance refers to methods performed on a proportion of treated subjects in comparison with untreated subjects where: a) a decreased level of a specific immunological response (thought to be mediated at least in part by antigen-specific effector T lymphocytes, B lymphocytes, antibody, or their equivalents); b) a delay in the onset or progression of a specific immunological response; or c) a reduced risk of the onset or progression of a specific immunological response.
  • Specific immunological tolerance occurs when immunological tolerance is preferentially invoked against certain antigens in comparison with others.
  • Non-Specific immunological tolerance occurs when immunological tolerance is invoked indiscriminately against antigens which lead to an inflammatory immune response.
  • Quasi-Specific” immunological tolerance occurs when immunological tolerance is invoked semi-discriminately against antigens which lead to a pathogenic immune response but not to others which lead to a protective immune response.
  • a proxy for tolerogenic activity is the ability of a particle to stimulate the production of an appropriate cytokine at the target site.
  • the immunoregulatory cytokine released by T suppressor cells at the target site is thought to be TGF- ⁇ (Miller et al., Proc. Natl. Acad. Sci. USA 89:421, 1992).
  • Other factors that may be produced during tolerance are the cytokines IL-4 and IL-10, and the mediator PGE.
  • lymphocytes in tissues undergoing active immune destruction secrete cytokines such as IL-1, IL-2, IL-6, and IFN ⁇ .
  • the efficacy of a modified particle can be evaluated by measuring its ability to stimulate the appropriate type of cytokines
  • a rapid screening test for modified particles, effective mucosal binding components, effective combinations, or effective modes and schedules of mucosal administration can be conducted using animal model systems.
  • Animals are treated at a mucosal surface with the test particle composition, and at some time are challenged with administration of the disease causing antigen or an infectious agent.
  • Spleen cells are isolated, and cultured in vitro in the presence of the disease causing antigen or an antigent derived from the infectious gent at a concentration of about 50 ⁇ g/mL. Cytokine secretion into the medium can be quantitated by standard immunoassay.
  • the ability of the particles to suppress the activity of cells can be determined using cells isolated from an animal immunized with the modified particles, or by creating a cell line responsive to a disease causing antigen or viral antigen target antigen (Ben-Nun et al., Eur. J. Immunol. 11:195, 1981).
  • the suppressor cell population is mildly irradiated (about 1000 to 1250 rads) to prevent proliferation, the suppressors are co-cultured with the responder cells, and then tritiated thymidine incorporation (or MTT) is used to quantitate the proliferative activity of the responders.
  • the suppressor cell population and the responder cell population are cultured in the upper and lower levels of a dual chamber transwell culture system (Costar, Cambridge Mass.), which permits the populations to coincubate within 1 mm of each other, separated by a polycarbonate membrane (WO 93/16724).
  • a dual chamber transwell culture system Costar, Cambridge Mass.
  • WO 93/16724 a polycarbonate membrane
  • compositions and modes of administration for treatment of specific disease can also be elaborated in a corresponding animal disease model.
  • the ability of the treatment to diminish or delay the symptomatology of the disease is monitored at the level of circulating biochemical and immunological hallmarks of the disease, immunohistology of the affected tissue, and gross clinical features as appropriate for the model being employed.
  • animal models that can be used for testing are included in the following section.
  • the invention contemplates modulation of tolerance by modulating TH1 response, TH2 response, TH17 response, or a combination of these responses.
  • Modulating TH1 response encompasses changing expression of, e.g., interferon-gamma.
  • Modulating TH2 response encompasses changing expression of, e.g., any combination of IL-4, IL-5, IL-10, and IL-13.
  • an increase (decrease) in TH2 response will comprise an increase (decrease) in expression of at least one of IL-4, IL-5, IL-10, or IL-13; more typically an increase (decrease) in TH2 response will comprise an increase in expression of at least two of IL-4, IL-5, IL-10, or IL-13, most typically an increase (decrease) in TH2 response will comprise an increase in at least three of IL-4, IL-5, IL-10, or IL-13, while ideally an increase (decrease) in TH2 response will comprise an increase (decrease) in expression of all of IL-4, IL-5, IL-10, and IL-13.
  • Modulating TH17 encompasses changing expression of, e.g., TGF-beta, IL-6, IL-21 and IL-23, and effects levels of IL-17, IL-21 and IL-22.
  • Tolerance to autoantigens and autoimmune disease is achieved by a variety of mechanisms including negative selection of self-reactive T cells in the thymus and mechanisms of peripheral tolerance for those autoreactive T cells that escape thymic deletion and are found in the periphery.
  • mechanisms that provide peripheral T cell tolerance include “ignorance” of self antigens, anergy or unresponsiveness to autoantigen, cytokine immune deviation, and activation-induced cell death of self-reactive T cells.
  • regulatory T cells have been shown to be involved in mediating peripheral tolerance. See, for example, Walker et al. (2002) Nat. Rev. Immunol. 2: 11-19; Shevach et al. (2001) Immunol. Rev. 182:58-67.
  • peripheral tolerance to an autoantigen is lost (or broken) and an autoimmune response ensues.
  • APCs antigen presenting cells
  • TLR innate immune receptors were shown to break self-tolerance and result in the induction of EAE (Waldner et al. (2004) J. Clin. Invest. 113:990-997).
  • the invention provides methods for increasing antigen presentation while suppressing or reducing TLR7/8, TLR9, and/or TLR 7/8/9 dependent cell stimulation.
  • administration of particular modified particles results in antigen presentation by DCs or APCs while suppressing the TLR 7/8, TLR9, and/or TLR7/8/9 dependent cell responses associated with immunostimulatory polynucleotides.
  • Such suppression may include decreased levels of one or more TLR-associated cytokines.
  • this invention provides novel compounds that have biological properties useful for the treatment of Mac-1 and LFA-1 mediated disorders.
  • compositions which comprise the carboxylated particles and optionally comprise a pharmaceutically acceptable carrier.
  • these compositions optionally further comprise one or more additional therapeutic agents.
  • the modified particles of the current invention may be administered to a patient in need thereof in combination with the administration of one or more other therapeutic agents.
  • additional therapeutic agents for conjoint administration or inclusion in a pharmaceutical composition with a compound of this invention may be an approved anti-inflammatory agent, or it may be any one of a number of agents undergoing approval in the Food and Drug Administration that ultimately obtain approval for the treatment of any disorder characterized by an uncontrolled inflammatory immune response or a bacterial or viral infection.
  • certain of the modified particles of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof.
  • compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogenfree water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as, for example, water or other solvents, solubil
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of drug release can be controlled.
  • biodegradable polymers include (poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the modified particles are mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and gly
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the modified particles can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose and starch.
  • Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the modified particles only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • the present invention encompasses pharmaceutically acceptable topical formulations of the inventive modified particles.
  • pharmaceutically acceptable topical formulation means any formulation which is pharmaceutically acceptable for intradermal administration of modified microparticles of the invention by application of the formulation to the epidermis.
  • the topical formulation comprises a carrier system.
  • Pharmaceutically effective carriers include, but are not limited to, solvents (e.g., alcohols, poly alcohols, water), creams, lotions, ointments, oils, plasters, liposomes, powders, emulsions, microemulsions, and buffered solutions (e.g., hypotonic or buffered saline) or any other carrier known in the art for topically administering pharmaceuticals.
  • solvents e.g., alcohols, poly alcohols, water
  • creams e.g., lotions, ointments, oils, plasters, liposomes, powders, emulsions, microemulsions, and buffered solutions (e.g., hypotonic or buffered saline) or any other carrier known in the art for topically administering pharmaceuticals.
  • buffered solutions e.g., hypotonic or buffered saline
  • the topical formulations of the invention may comprise excipients.
  • Any pharmaceutically acceptable excipient known in the art may be used to prepare the inventive pharmaceutically acceptable topical formulations.
  • excipients that can be included in the topical formulations of the invention include, but are not limited to, preservatives, antioxidants, moisturizers, emollients, buffering agents, solubilizing agents, other penetration agents, skin protectants, surfactants, and propellants, and/or additional therapeutic agents used in combination to the modified particles.
  • Suitable preservatives include, but are not limited to, alcohols, quaternary amines, organic acids, parabens, and phenols.
  • Suitable antioxidants include, but are not limited to, ascorbic acid and its esters, sodium bisulfite, butylated hydroxytoluene, butylated hydroxyanisole, tocopherols, and chelating agents like EDTA and citric acid.
  • Suitable moisturizers include, but are not limited to, glycerine, sorbitol, polyethylene glycols, urea, and propylene glycol.
  • Suitable buffering agents for use with the invention include, but are not limited to, citric, hydrochloric, and lactic acid buffers.
  • Suitable solubilizing agents include, but are not limited to, quaternary ammonium chlorides, cyclodextrins, benzyl benzoate, lecithin, and polysorbates.
  • Suitable skin protectants that can be used in the topical formulations of the invention include, but are not limited to, vitamin E oil, allatoin, dimethicone, glycerin, petrolatum, and zinc oxide.
  • the pharmaceutically acceptable topical formulations of the invention comprise at least the modified particles of the invention and a penetration enhancing agent.
  • the choice of topical formulation will depend or several factors, including the condition to be treated, the physicochemical characteristics of the inventive compound and other excipients present, their stability in the formulation, available manufacturing equipment, and costs constraints.
  • the term “penetration enhancing agent” means an agent capable of transporting a pharmacologically active compound through the stratum corneum and into the epidermis or dermis, preferably, with little or no systemic absorption.
  • a wide variety of compounds have been evaluated as to their effectiveness in enhancing the rate of penetration of drugs through the skin. See, for example, Percutaneous Penetration Enhancers, Maibach H. I.
  • penetration agents for use with the invention include, but are not limited to, triglycerides (e.g., soybean oil), aloe compositions (e.g., aloe-vera gel), ethyl alcohol, isopropyl alcohol, octolyphenylpolyethylene glycol, oleic acid, polyethylene glycol 400, propylene glycol, N-decylmethylsulfoxide, fatty acid esters (e.g., isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate) and N-methylpyrrolidone.
  • triglycerides e.g., soybean oil
  • aloe compositions e.g., aloe-vera gel
  • ethyl alcohol isopropyl alcohol
  • octolyphenylpolyethylene glycol oleic acid
  • polyethylene glycol 400 propylene glycol
  • compositions may be in the form of ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • formulations of the compositions according to the invention are creams, which may further contain saturated or unsaturated fatty acids such as stearic acid, palmitic acid, oleic acid, palmito-oleic acid, cetyl or oleyl alcohols, stearic acid being particularly preferred.
  • Creams of the invention may also contain a non-ionic surfactant, for example, polyoxy-40-stearate.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are made by dissolving or dispensing the compound in the proper medium.
  • penetration enhancing agents can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the modified particles can be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the modified particles.
  • a nonaqueous (e.g., fluorocarbon propellant) suspension could be used.
  • an aqueous aerosol is made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically acceptable carriers and stabilizers.
  • the carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
  • Aerosols generally are prepared from isotonic solutions.
  • modified particles and pharmaceutical compositions of the present invention can be formulated and employed in combination therapies, that is, the compounds and pharmaceutical compositions can be formulated with or administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another anti-inflammatory agent), or they may achieve different effects (e.g., control of any adverse effects).
  • the pharmaceutical compositions containing the modified particles of the present invention further comprise one or more additional therapeutically active ingredients (e.g., anti-inflammatory and/or palliative).
  • additional therapeutically active ingredients e.g., anti-inflammatory and/or palliative.
  • palliative refers to treatment that is focused on the relief of symptoms of a disease and/or side effects of a therapeutic regimen, but is not curative.
  • palliative treatment encompasses painkillers, antinausea medications and anti-sickness drugs.
  • the invention provides methods of regulating an immune response in an individual, preferably a mammal, more preferably a human, comprising administering to the individual the modified particles described herein.
  • Methods of immunoregulation provided by the invention include those that suppress and/or inhibit an innate immune response or an adaptive immune response, including, but not limited to, an immune response stimulated by immunostimulatory polypeptides or viral or bacterial components.
  • the modified particles are administered in an amount sufficient to regulate an immune response.
  • regulation of an immune response may be humoral and/or cellular, and is measured using standard techniques in the art and as described herein.
  • the individual suffers from a disorder associated with unwanted immune activation, such as allergic disease or condition, allergy and asthma.
  • a disorder associated with unwanted immune activation such as allergic disease or condition, allergy and asthma.
  • An individual having an allergic disease or asthma is an individual with a recognizable symptom of an existing allergic disease or asthma.
  • the individual suffers from a disorder associated with unwanted immune activation, such as atherosclerosis, ischemic reperfusion injury, and myocardial infarction.
  • a disorder associated with unwanted immune activation such as atherosclerosis, ischemic reperfusion injury, and myocardial infarction.
  • the individual suffers from a disorder associated with unwanted immune activation, such as autoimmune disease and inflammatory disease.
  • a disorder associated with unwanted immune activation such as autoimmune disease and inflammatory disease.
  • An individual having an autoimmune disease or inflammatory disease is an individual with a recognizable symptom of an existing autoimmune disease or inflammatory disease.
  • Autoimmune diseases can be divided in two broad categories: organ-specific and systemic. Autoimmune diseases include, without limitation, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type I diabetes mellitus, type II diabetes mellitus, multiple sclerosis (MS), immune-mediated infertility such as premature ovarian failure, scleroderma, Sjogren's disease, vitiligo, alopecia (baldness), polyglandular failure, Grave's disease, hypothyroidism, polymyositis, pemphigus vulgaris, pemphigus foliaceus, inflammatory bowel disease including Crohn's disease and ulcerative colitis, autoimmune hepatitis including that associated with hepatitis B virus (HBV) and hepatitis C virus (HCV), hypopituitarism, graft-versus-host disease (GvHD), myocarditis, Addison's disease, autoimmune
  • Autoimmune diseases may also include, without limitation, Hashimoto's thyroiditis, Type I and Type II autoimmune polyglandular syndromes, paraneoplastic pemphigus, bullus pemphigoid, dermatitis herpetiformis, linear IgA disease, epidermolysis bullosa acquisita, erythema nodosa, pemphigoid gestationis, cicatricial pemphigoid, mixed essential cryoglobulinemia, chronic bullous disease of childhood, hemolytic anemia, thrombocytopenic purpura, Goodpasture's syndrome, autoimmune neutropenia, myasthenia gravis, Eaton-Lambert myasthenic syndrome, stiff-man syndrome, acute disseminated encephalomyelitis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy with conduction block, chronic neuropathy with monoclonal gammopathy, opson
  • Animal models for the study of autoimmune disease are known in the art.
  • animal models which appear most similar to human autoimmune disease include animal strains which spontaneously develop a high incidence of the particular disease.
  • Examples of such models include, but are not limited to, the nonobeses diabetic (NOD) mouse, which develops a disease similar to type 1 diabetes, and lupus-like disease prone animals, such as New Zealand hybrid, MRL-Fas lpr and BXSB mice.
  • NOD nonobeses diabetic
  • Animal models in which an autoimmune disease has been induced include, but are not limited to, experimental autoimmune encephalomyelitis (EAE), which is a model for multiple sclerosis, collagen-induced arthritis (CIA), which is a model for rheumatoid arthritis, and experimental autoimmune uveitis (EAU), which is a model for uveitis.
  • Animal models for autoimmune disease have also been created by genetic manipulation and include, for example, IL-2/IL-10 knockout mice for inflammatory bowel disease, Fas or Fas ligand knockout for SLE, and IL-1 receptor antagonist knockout for rheumatoid arthritis.
  • the individual suffers from a bacterial or viral infection.
  • An individual having a bacterial or viral infection is an individual with a recognizable symptom of an existing bacterial or viral infection.
  • a non-limiting list of viral infections treatable with the modified particles of the current invention includes herpes virus infections, hepatitis virus infections, west nile virus infections, flavivrus infections, influenza virus infections, rhinovirus infections, papillomavirus infections, paromyxovirus infections, parainfluenza virus infections, and retrovirus infections.
  • Preferred viruses are those viruses that infect the central nervous system of the subject. Most preferred viruses are those that cause encephalitis or meningitis.
  • a non-limiting list of bacterial infections treatable with the modified particles of the current invention include staphlococcus infections, streptococcus infections, mycobacterial infections, bacillus infections, Salmonella infections, Vibrio infections, spirochete infections, and Neisseria infections.
  • the invention relates to uses of compositions of this invention prior to the onset of disease. In other embodiments, the invention relates to uses of the compositions of this invention to inhibit ongoing disease. In some embodiments, the invention relates to ameliorating disease in a subject. By ameliorating disease in a subject is meant to include treating, preventing or suppressing the disease in the subject.
  • the invention relates to preventing the relapse of disease.
  • an unwanted immune response can occur at one region of a peptide (such as an antigenic determinant).
  • Relapse of a disease associated with an unwanted immune response can occur by having an immune response attack at a different region of the peptide.
  • the carboxylated particles of the current invention are free from attached peptides or antigenic moieties, the particles will be effective against multiple epitopes.
  • T-cell responses in some immune response disorders, including MS and other TH1/17-mediated autoimmune diseases can be dynamic and evolve during the course of relapsing-remitting and/or chronic-progressive disease.
  • the dynamic nature of the T-cell repertoire has implications for treatment of certain diseases, since the target may change as the disease progresses. Previously, pre-existing knowledge of the pattern of responses was necessary to predict the progression of disease.
  • the present invention provides compositions that can prevent the effect of dynamic changing disease, a function of “epitope spreading.”
  • a known model for relapse is an immune reaction to proteolipid protein (PLP) as a model for multiple sclerosis (MS).
  • PLP proteolipid protein
  • MS multiple sclerosis
  • the hypersensitivity can be any one of types I, II, III, and IV. Immediate (type I) hypersensitivity.
  • the frequency of administration will typically correspond with the timing of allergen exposure. Suitable animal models are known in the art (for example, Gundel et al., Am. Rev. Respir. Dis. 146:369, 1992, Wada et al., J. Med. Chem. 39, 2055, 1996; and WO 96/35418).
  • Tissues that are transplanted include (but are not limited to) whole organs such as kidney, liver, heart, lung; organ components such as skin grafts and the cornea of the eye; and cell suspensions such as bone marrow cells and cultures of cells selected and expanded from bone marrow or circulating blood, and whole blood transfusions.
  • a serious potential complication of any transplantation ensues from antigenic differences between the host recipient and the engrafted tissue.
  • an immunological assault of the graft by the host or of the host by the graft, or both, may occur.
  • the extent of the risk is determined by following the response pattern in a population of similarly treated subjects with a similar phenotype, and correlating the various possible contributing factors according to well accepted clinical procedures.
  • the immunological assault may be the result of a preexisting immunological response (such as preformed antibody), or one that is initiated about the time of transplantation (such as the generation of TH cells).
  • Antibody, T helper (TH) cells, or cytotoxic T (Tc) cells may be involved in any combination with each other and with various effector molecules and cells.
  • the antigens which are involved in the immune response are generally not known, therefore posing difficulties in designing antigen-specific therapies or inducing antigen-specific tolerance.
  • the modified particles of the current invention are particularly useful in preventing the rejection of organs because no attached peptides or antigens need to be conjugated to the modified particles in order for the particles to be effective in inducing tolerance or ameliorate an inflammatory immune response.
  • Certain embodiments of the invention relate to decreasing the risk of host versus graft disease, leading to rejection of the tissue graft by the recipient.
  • the treatment may be performed to prevent or reduce the effect of a hyperacute, acute, or chronic rejection response.
  • Treatment is preferentially initiated sufficiently far in advance of the transplant so that tolerance will be in place when the graft is installed; but where this is not possible, treatment can be initiated simultaneously with or following the transplant. Regardless of the time of initiation, treatment will generally continue at regular intervals for at least the first month following transplant.
  • follow-up doses may not be required if a sufficient accommodation of the graft occurs, but can be resumed if there is any evidence of rejection or inflammation of the graft.
  • the tolerization procedures of this invention may be combined with other forms of immunosuppression to achieve an even lower level of risk.
  • West Nile Virus Sarafend strain
  • PFU plaque forming units
  • mice Eight to twelve-week old female C57BL/6 (CD45.2) and congenic B6.5JL-Ptprc a Pep3 b /BoyJ (CD45.1) mice were obtained from the Animal Resources Center, Western Australia. C57BL/6-7.2fms-EGFP transgenic (CD45.2) mice were obtained from the Transgenic Animal Resources Center Queensland, Australia. All procedures were performed with permission of the University of Sydney Animal Ethics Committee. All animals were housed under class II biohazard conditions in hepa-filter top cages. Food and water was provided ad libitum.
  • mice were weighed twice daily following infection. Mice were sacrificed under anaesthesia by cardiac perfusion using 40 ml of ice cold PBS. For histology, mice were further perfused with 20 ml of 4% paraformaldehyde (Sigma Aldrich, St Louis, USA) in PBS.
  • tissue samples were dissected from animals and disassociated with a power homogeniser (Tissue Tearor, Biospec, Bartles, Okla., USA). Briefly, five-fold dilutions of clarified homogenates were prepared in Roswell Park Memorial Institute 1640 media (RPMI; CSL Biosciences), and used to infect confluent BHK cells in 6-well plates (1 ⁇ 10 6 cells seeded overnight in 2 mL RPMI).
  • RPMI Roswell Park Memorial Institute 1640 media
  • mice were irradiated with one dose of 950 rads. Twelve hours later, mice were reconstituted with 10 7 bone marrow cells from C57BL/6-7.2fms-EGFP donors. Mice were given sulfamethoxazole (Sigma Aldrich) and trimethoprim (Sigma Aldrich) in the drinking water for 10 days following irradiation. Mice were infected with WNV six weeks after irradiation, as described above. Chimerism was checked using flow cytometry and was invariably found to be 96-99% of donor origin as previously demonstrated (Getts et al., J. Neurochem. 103: 1019, 2007).
  • FITC or Bright Blue (BB) Flouresbrite naked and carboxylated polystyrene beads were obtained from Polyscience, NY, USA.
  • high dose survival studies (6 ⁇ 10 4 PFU WNV i.n.) mice were given one dose of beads each day beginning on day 6 post infection If required, mice were given further injections each day until weight had restabilized.
  • low dose survival studies (6 ⁇ 10 3 PFU WNV i.n.), mice were either injected with beads from d6 p.i., or when significant weight loss was recorded (4-6% of total body weight). Mice were injected with 300 ul of beads once a day for 5 days, or until weight had restabilized.
  • mice 6 ⁇ 10 4 or 6 ⁇ 10 3 -infected mice were injected with 300 ⁇ l of beads on either d6 p.i., or when significant weight loss was recorded, and culled when required. Organs were harvested for immunohistochemistry, flow cytometry, plaque assay, and cytokine analysis, as described below.
  • Fluoresence immunohistochemistry was conducted on brain, spleen, liver, lungs and kidneys collected from C57BL/6 and cFMS-EGFP (into B6.5JL-Ptprc a Pep3 b /BoyJ) chimeras. Following perfusion, organs were fixed in 4% paraformaldehyde at 4° C. for 4 hours and then immersed in 30% sucrose overnight, before being frozen in Optimum Cutting Temperature Compound (OCT; Tissue-Tek, Tokyo Japan). Eight-micron tissue sections were cut on a cryostat microtome and air-dried. Fluorescence IHC was performed as previously described, (Getts et al, J Exp Med.
  • TSA kit tyramide-based amplification system
  • Vector DAPI-anti fade
  • leukocytes were obtained from the brains of PBS-perfused mice by digesting brains for 60 minutes at 37° C. in PBS with deoxy-ribonuclease (0.005 g/ml; Sigma Aldrich) and collagenase IV (0.05 g/ml; Sigma Aldrich). Digestion was stopped with 10% FCS, and the homogenate was passed through a 70 ⁇ m nylon cell strainer (Becton Dickinson, NJ, USA). The pellet, obtained after 10 minutes centrifugation at 340 ⁇ g, was resuspended in 30% Percoll (Amersham, Norway) and layered over 80% Percoll. Leukocytes were collected from the 30%/80% interface after centrifugation at 1140 ⁇ g for 25 minutes at room temperature. The same protocol is also used to derive leukocytes from the liver, with the tissue weighed before processing.
  • the right femur was dissected out and bone marrow cells flushed out using PBS loaded syringes.
  • femurs and tibias from at least 4 mice were utilized.
  • the cellular suspension achieved after flushing was filtered through a 70 ⁇ m cell strainer and centrifuged for 5 mins at 340 g. Red blood cells in the resulting pellet were lysed in NH 4 Cl-based red cell lysis buffer (BD Pharm LyseTM; BD Pharmingen), before centrifugation for 5 mins at 340 ⁇ g.
  • BD Pharm LyseTM NH 4 Cl-based red cell lysis buffer
  • peripheral blood blood was collected via cardiac puncture and immediately transferred into citrate buffer (mMol, Sigma Alrich).
  • the resulting suspension was layered over 70% Percoll and centrifuged at 1140 ⁇ g for 20 minutes at room temperature with the brake off. The interface was collected and the cells washed once in PBS, centrifuged at 340 ⁇ g.
  • spleens were passed through a 7070 ⁇ m cell strainer and centrifuged for 5 mins at 340 g. Red blood cells in the resulting pellet were lysed in NH 4 Cl-based red cell lysis buffer (BD Pharm LyseTM; BD Pharmingen), before centrifugation for 5 mins at 340 ⁇ g.
  • Cell surface molecule expression was measured and cell sorts carried out on a FACS ARIA (Becton Dickinson), equipped with an Argon ion and HeNe laser. Viable populations were gated by forward and side scatter and identified fluorescent populations determined by forward-gating thereafter. Sorting was carried out using specific fluorescent and scatter parameters identifying the population of interest. Sorting stringencies was set to purity to achieve >98% purity for bone marrow populations.
  • Ly6C hi /cFMS-EGFP + /CD11b + and Ly6C lo /Cfms-EGFP + /CD11b + populations were sorted from day 6 intranasally WNV-infected mice.
  • Ly6C hi BM was labeled with 10 mM cell tracker orange (CMTMR [5-(and -6)-(((4-chloromethyl) benzoyl) amino) tetramethylrhodamine)-mixed isomers; Invitrogen). Sorted cells were centrifuged and raised in 1 ml PBS containing 10 ⁇ M CMTMR. Cells were stained for 10 min before the reaction was stopped with 10% FCS.
  • CTMR cell tracker orange
  • CMTMR Ly6C hi BM cells were washed in 50 ml PBS at least three times. Labeled CMTMR Ly6C hi BM cells were then mixed 1:1 with Ly6C lo cells, which, except for the addition of CMTMR, had been treated similarly to Ly6C hi populations. A total of 2 ⁇ 10 6 BM cells were i.v. injected into either day 6.5 WNV-infected or mock-infected Ly5.1-057BL/6 congenic mice. This was immediately followed by an intravenous injection of 300 ul BB polystyrene beads. 12 h later, brains, spleens and livers were harvested as described above. The presence of donor cells was investigated using flow cytometry, both using cFMS-EGFP and CMTMR-cell tracker orange.
  • Multiplexed plate ELISAs were performed according to the manufacturers instructions (Quansys Biosciences, Logan, Utah, USA). Briefly, brain, spleen, and liver tissue were homogenized in PBS, clarified by a 1000 ⁇ g spin, and stored at ⁇ 20° C. until the assay was performed. Serum samples were also used. Thawed samples and standards were diluted in the provided buffer, and 30 ⁇ l of each were plated in each well that contains 16 spots each containing a capture antibody for a particular soluble protein. Plates were then incubated for 1 hour on an orbital shaker at 120 r.p.m. Plates were washed 3 times, and 30 ⁇ l of detection antibody was added to each well and incubated for another hour.
  • mice C57BL/6 mice were injected sub-cutaneously with emulsion containing 0.1 mg MOG Peptide (MEVGWYRSPFSRVVHLYRNGK; Auspep, Parkville, Victoria, Australia; >95% HPLC purified) and Complete Freund's adjuvant containing 2 mg/mL Mycobacterium tuberculosis (Sigma Aldrich). Two days later, mice were administered 500 ⁇ l Pertussis toxin (Sigma Aldrich) i.p.
  • MOG Peptide MEVGWYRSPFSRVVHLYRNGK
  • mice were monitored for disease progression, and graded on the following scale: 1, limp tail and/or weakness of 1 hind limb; 2, weakness in more than one limb, gait disturbance; 3, paralysis in 1 limb; 4, paralysis in more than one limb, incontinence; 5, moribund.
  • FIG. 1A High dose infection of C57BL/6 mice with 6 ⁇ 10 4 PFU WNV i.n. results in 100% mortality on d7 p.i.
  • FIG. 1A Macrophages and immigrant microglia, which we have previously shown to derive from circulating Ly6c hi monocyte precursors (Getts et al, J Exp Med. 29: 2319, 2007), infiltrate the WNV-infected brain from d5 p.i. T cells, NK cells, and neutrophils also enter the CNS from this timepoint onwards, with the peak of infiltration seen on d7 p.i. ( FIG. 1F-H , FIG.
  • Brain virus titre also exponentially increases from d5 p.i., reaching high levels on d7 p.i. ( FIG. 1C ), and body weight of infected mice significantly decreases from d5 p.i. until death ( FIG. 1B ).
  • mice with 10-fold less virus i.e. 6 ⁇ 10 3 PFU i.n.
  • Some variability occurs in mortality rate when comparing independent experiments, which ranges between 40-60% ( FIG. 1A ); however, a strong correlation between the percentage of weight loss and virus titre/infiltration has been consistently shown ( FIG. 1B-H , FIG. 2A-E ).
  • the daily monitoring of mouse weight has proven to be a reliable method to predict the outcome of infection in individuals, and is indicative of when mice require intervention in order to survive infection ( FIG. 1B ).
  • mice that do not lose weight after inoculation with 6 ⁇ 10 3 WNV do not succumb to infection, and are immune to subsequent reinfection with 6 ⁇ 10 4 ( FIG. 1A-B ). These mice do not show any symptoms of illness upon initial infection or high dose reinfection, including weight loss. Conversely, mice that lose a significant amount of weight compared to the normal fluctuations of mock-infected controls (usually >4% of body weight in a 24 hour time period) continue to lose weight, typically for 2-3 days before death occurs. In this model of encephalitis, the majority of mice that succumb to infection begin to lose weight between d6 and d11 post infection, and death occurs before d16 p.i. These mice show high titres of virus in the brain at TOD, comparable to d7 mice infected with 6 ⁇ 10 4 ( FIG. 1C ).
  • mice 6 ⁇ 10 3 -infected mice were weighed daily and sacrificed on d0-d14, with brains harvested for flow cytometry and plaque assay. Some correlation was shown between percentage weight loss at time of sacrifice and virus titre ( FIG. 2F ), or leukocyte infiltration ( FIG. 2G ). However, a comparison between virus titre and leukocyte infiltration revealed that some mice had high titres of virus without significant infiltration ( FIG. 2H ), and while some of these mice had also lost a significant amount of weight, others had not ( FIG. 2F ).
  • mice Because mice have to be sacraficed to determine virus titres in the brain, it is unclear whether these mice that had virus in the brain without significant weight loss or leukocyte infiltration would clear the virus without showing weight loss or infiltration, or if the high virus titre seen precedes infiltration of the brain/weight loss.
  • Fluorescent beads have been used frequently in the literature to follow the trafficking of monocyte subsets in various in vivo models of disease. However, these studies overlook the potential influence that these theoretically “inert” beads may have on monocyte function, and as a result, the outcome of disease.
  • mice were weighed daily ( FIG. 3E-G ), and 4.41 ⁇ 10 9 carboxylated polystyrene beads were administered if significant weight loss was detected in a 24-hour time period (usually >4% of total body weight, as compared to the normal fluctuations of mock-infected controls).
  • FIG. 3D we were able to increase survival of mice that would usually continue to lose weight and die without intervention, by 60% (40-80% in independent experiments) ( FIG. 3D ).
  • FIG. 3E , G mice that did not lose a significant amount of weight at any time showed similar stability in weight as PBS-infected controls ( FIG. 3E-F ).
  • mice were treated with carboxylated beads for 5 consecutive days upon the initial detection of significant weight loss. In some mice, 5 days of bead treatment was sufficient and weight remained stabilized after bead injection ceased and these mice went on to survive infection without further intervention ( FIG. 4A-B ). However, some mice began to lose weight again when bead treatment ceased at 5 days, so treatment was recommenced until weight restabalized, and these mice also survived long-term ( FIG. 4C-D ).
  • mice that had not lost weight were also bead- or PBS-treated on d8 as controls for the experiment.
  • FIGS. 4D-L mice that did not lose weight on d8 p.i. but were bead- ( FIG. 4H-I ) or PBS-treated ( FIG.
  • mice that did lose weight on d8 p.i. and were treated with PBS showed no infiltration of the brain by monocyte-derived macrophages or immigrant microglia, T cells, NK cells or neutrophils, with the main population isolated being the CD45 lo/int CD11b + resident microglia.
  • FIG. 4F-G a massive infiltration of the brain was evident on d9 p.i.
  • FIG. 4L the main population being the CD45 hi inflammatory monocyte-derived macrophages
  • FIG. 4J-L Flow cytometry of 10 3 -infected mice treated with bead or PBS upon weight loss needs to be repeated to show that reductions in infiltration occur when mice are bead-treated across days 6-14 p.i.
  • mice that did not lose a significant amount of weight showed a similar pattern of stability as PBS-infected controls (data not shown), whereas mice that were treated with either carboxylated or naked beads ( FIG. 5B-C ) eventually stabilized and survived, or continued to lose weight and died 2-4 days later. All mice that lost weight and were treated with PBS (B, D) continued to lose weight and died 2-5 days later.
  • Ly6c hi and Ly6c lo/int populations of macrophages were significantly reduced by both bead treatments, with no changes seen in the small population of Ly6c ⁇ cells.
  • CD45 int activated microglia reductions in the Ly6c hi subset were only seen with carboxylated bead treatment, but reductions in Ly6c lo/int and Ly6c ⁇ subsets were seen with both bead treatments. No changes were seen in the small subset of Ly6c hi CD45 lo resting microglia, however both bead treatments reduced Ly6c lo/int and Ly6c ⁇ subsets significantly.
  • bead+ cells were primarily CD11b + , CD11c + and Ly6c + .
  • the Ly6c ⁇ /lo population was found to take up both types of beads ( FIG. 8B ). However, only carboxylated beads increased the total numbers of CD11b + CD11c + dendritic cells in the spleen, and of these, the Ly6c ⁇ /lo population. As there was no increase in bead ⁇ Ly6c ⁇ /lo dendritic cells, it is apparent that only bead + Ly6c ⁇ /lo dendritic cells traffic to the spleen after the uptake of carboxylated beads.
  • Ly6c hi inflammatory monocytes that take up beads in the circulation, divert to the spleen instead of trafficking to the brain, where they down regulate Ly6c expression, and upregulate CD11c expression as they differentiate into dendritic cells.
  • Ly6c lo/ ⁇ cells took up both bead types ( FIG. 8C ). With carboxylated bead treatment increases were seen in total numbers of CD11b ⁇ CD11c + dendritic cell populations, more specifically Ly6c lo/ ⁇ cells. Increases were seen in both bead + and bead ⁇ cells of this population, suggesting that not only bead + but also bead ⁇ cells increase in the spleen.
  • This population may comprise of splenic resident DC, non-myeloid DC recruited from the periphery, or may also potentially consist of inflammatory monocytes that have taken up beads, down regulated CD11b and Ly6c and upregulated CD11c expression.
  • Beads could also be detected in the liver, primarily in association with CD11b, CD11c and Ly6c-expressing cells ( FIG. 10A-I ).
  • CD11b + CD11c ⁇ monocytes FIG. 10J
  • CD11b + CD11c FIG. 10K
  • CD11b ⁇ CD11c + FIG. 10L
  • dendritic cells were found to take up beads in the liver.
  • a small number of beads were also detected in the bone marrow, in a small population of CD11b + CD11c + Ly6c + leukocytes ( FIG. 11A-G ).
  • FIG. 11A-G there were no significant increases or decreases found in any leukocyte populations of the bone marrow.
  • mice 6 ⁇ 10 3 WNV-infected mice were injected with a low dose of 0.1% or a high dose of 0.5% beads of 0.5, 0.05, or 3 ⁇ m carboxylated polystyrene beads in 300 ⁇ l PBS i.v., or PBS only, when significant weight loss was recorded.
  • Mice that were treated with a low dose of 0.5, 0.05, or 3 ⁇ m showed similar improvements in survival, of approximately 40-50% ( FIG. 12A ). However, high dose treatment of mice appeared to be detrimental to survival, with a much smaller improvement of 20%.
  • mice treated with the high dose of beads showed atypical symptoms of illness, and it could be speculated that the build up of such a high dose of beads in the vital organs over a number of days was detrimental to the mouse. This time course will be repeated, with the potential for including other lower doses of beads.
  • Flow cytometry will also be conducted in 6 ⁇ 10 4 WNV-infected mice treated on d6 p.i. with different sizes of beads.
  • WT mice infected with the high dose of 6 ⁇ 10 4 showed 100% mortality on d7 p.i., while RAG mice infected with the same dose began to die on d8 p.i., with some mice living up to d13 p.i.
  • WT mice infected with the lower dose of 6 ⁇ 10 3 showed 60% mortality by d8 p.i., but 40% long-term survival after this time point.
  • RAG mice infected with this same dose did not begin to die until d14 p.i., however by d16 all RAG mice were dead ( FIG. 13A-B ).
  • T cells are critical to control viral infection, as all of the RAG mice infected with the low dose succumb to disease whereas 40% of the WT mice survive with immunity.
  • RAG and WT mice were also infected with 6 ⁇ 10 3 PFU WNV and were weighed daily in order to test the efficacy of carboxylated beads in the absence of T cells. Upon significant weight loss (>4% in 24 hours) mice were treated with 4.41 ⁇ 10 9 carboxylated beads or PBS i.v. delivered in a 300 ul volume. There was no significant improvement in survival of RAG mice by bead injection ( FIG. 12F ). RAG mice continued to lose weight after bead or PBS injection and died 2-5 days later ( FIG. 12G ). This experiment needs to be repeated again to confirm results.
  • C57BL/6 mice will be primed with MOG and CFA adjuvant.
  • carboxylated particles will be administered intravenously, either very 8 hours, every 16 hours, every day or every 48 hours.
  • the severity of disease will be determined by changes in disease score. Infusion of particles will prevent migration of monocytes into the brain and subsequent T cell priming resulting in significant reductions in disease scores.
  • APO/E deficient mice will be fed a high fat diet. From 4 weeks of age, carboxylated particles will be administered intravenously, every 8 hours, every 16 hours, every 24 hours, every 48 hours, every 72 hours, once weekly, or once monthly. The severity of disease will be determined by changes in arterial histology. Infusion of particles will prevent migration of monocytes into the arterial wall and prevent subsequent immune sequelae critical to drive smooth muscle proliferation and intimal plaque formation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
US13/884,817 2010-11-12 2011-11-14 Modified immune-modulating particles Abandoned US20130323319A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/884,817 US20130323319A1 (en) 2010-11-12 2011-11-14 Modified immune-modulating particles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41301610P 2010-11-12 2010-11-12
US41301810P 2010-11-12 2010-11-12
PCT/US2011/060537 WO2012065153A2 (en) 2010-11-12 2011-11-14 Modified immune-modulating particles
US13/884,817 US20130323319A1 (en) 2010-11-12 2011-11-14 Modified immune-modulating particles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/060537 A-371-Of-International WO2012065153A2 (en) 2010-11-12 2011-11-14 Modified immune-modulating particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/624,461 Continuation US10471093B2 (en) 2010-11-12 2015-02-17 Modified immune-modulating particles

Publications (1)

Publication Number Publication Date
US20130323319A1 true US20130323319A1 (en) 2013-12-05

Family

ID=46051605

Family Applications (6)

Application Number Title Priority Date Filing Date
US13/884,817 Abandoned US20130323319A1 (en) 2010-11-12 2011-11-14 Modified immune-modulating particles
US14/624,461 Active US10471093B2 (en) 2010-11-12 2015-02-17 Modified immune-modulating particles
US16/150,806 Active US11020424B2 (en) 2010-11-12 2018-10-03 Modified immune-modulating particles
US16/654,918 Pending US20200030369A1 (en) 2010-11-12 2019-10-16 Modified Immune-Modulating Particles
US16/842,565 Abandoned US20200338116A1 (en) 2010-11-12 2020-04-07 Modified immune-modulating particles
US18/330,333 Pending US20240245719A1 (en) 2010-11-12 2023-06-06 Modified immune-modulating particles

Family Applications After (5)

Application Number Title Priority Date Filing Date
US14/624,461 Active US10471093B2 (en) 2010-11-12 2015-02-17 Modified immune-modulating particles
US16/150,806 Active US11020424B2 (en) 2010-11-12 2018-10-03 Modified immune-modulating particles
US16/654,918 Pending US20200030369A1 (en) 2010-11-12 2019-10-16 Modified Immune-Modulating Particles
US16/842,565 Abandoned US20200338116A1 (en) 2010-11-12 2020-04-07 Modified immune-modulating particles
US18/330,333 Pending US20240245719A1 (en) 2010-11-12 2023-06-06 Modified immune-modulating particles

Country Status (10)

Country Link
US (6) US20130323319A1 (de)
EP (1) EP2637697A4 (de)
JP (1) JP5909745B2 (de)
KR (2) KR101819688B1 (de)
CN (1) CN103429232B (de)
AU (2) AU2011325966B2 (de)
BR (1) BR112013011842A2 (de)
CA (2) CA2817755C (de)
MX (1) MX358598B (de)
WO (1) WO2012065153A2 (de)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150010631A1 (en) * 2013-03-13 2015-01-08 Cour Pharmaceuticals Development Company Immune-modifying nanoparticles for the treatment of inflammatory diseases
US9522180B2 (en) 2013-08-13 2016-12-20 Northwestern University Peptide conjugated particles
US9999600B2 (en) 2013-04-03 2018-06-19 N-Fold Llc Nanoparticle compositions
US10201596B2 (en) 2012-06-21 2019-02-12 Northwestern University Peptide conjugated particles for the treatment of allergy
US10471093B2 (en) 2010-11-12 2019-11-12 Cour Pharmaceuticals Development Company. Modified immune-modulating particles
WO2019217780A1 (en) 2018-05-11 2019-11-14 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
US11071776B2 (en) 2012-04-23 2021-07-27 N-Fold Llc Nanoparticles for treatment of allergy

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184976A2 (en) * 2012-06-06 2013-12-12 Northwestern University Compositions and methods for antigen-specific tolerance
EP2928500B1 (de) 2012-12-04 2019-03-06 Phosphorex Inc. Mikropartikel und nanopartikeln mit negativen oberflächenladungen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043075A1 (en) * 2002-09-04 2004-03-04 Vladimir Ritter Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
JPH06157592A (ja) 1992-11-24 1994-06-03 Hitachi Chem Co Ltd ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−１抗体の製造方法
US5804201A (en) 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5
EP1212086B8 (de) * 1999-08-18 2008-01-02 Industry-Academic Cooperation Foundation, The Catholic University of Korea Agent zur induktion einer immunologischen toleranz
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
EP1311549A2 (de) 2000-08-22 2003-05-21 Micromet AG Zusammensetzung zur eliminierung autoreaktiver b-zellen
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
AU2003216851B2 (en) 2002-03-19 2008-04-17 Powderject Research Limited Imidazoquinoline adjuvants for vaccines
WO2003092654A1 (en) 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
WO2004006951A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
AU2003302226A1 (en) 2002-09-24 2004-06-30 University Of Kentucky Research Foundation Nanoparticle-based vaccine delivery system containing adjuvant
WO2005000272A1 (en) 2003-06-04 2005-01-06 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
CA2545276C (en) 2003-11-05 2016-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
AU2006282042B2 (en) 2005-06-17 2011-12-22 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
ATE458762T1 (de) 2005-07-01 2010-03-15 Hoffmann La Roche Carboxylierte latexteilchen
WO2007008755A2 (en) 2005-07-08 2007-01-18 The Board Of Regents, The University Of Texas System Surface functionalization of polymeric materials
GB0514262D0 (en) 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US20100028450A1 (en) 2006-01-25 2010-02-04 The Board Of Trustees Of The University Of Illinoi S Tolerogenic biodegradable artificial antigen presenting system
WO2007094003A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
JP2009544750A (ja) 2006-07-28 2009-12-17 ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ 治療
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
US20090214474A1 (en) 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2117600B1 (de) 2006-12-18 2012-12-05 Colorobbia Italia S.p.a. Magnetische nanoteilchen zur anwendung bei hyperthermie, herstellung davon und verwendung in konstrukten mit einer pharmakologischen anwendung
CN101678090B (zh) 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
EP2211841A4 (de) 2007-10-15 2013-03-13 Cooperative Res Ct For Asthma Verfahren zur prophylaxe und mittel zur verwendung darin
WO2009052561A1 (en) 2007-10-22 2009-04-30 The Walter And Eliza Hall Institute Of Medical Research Compositions and methods for manipulating an immune response
GB0721081D0 (en) 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
EP2057998A1 (de) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Verwendung modifizierter Zellen zur Behandlung von multipler Sklerose
US20090123509A1 (en) 2007-11-08 2009-05-14 Cory Berkland Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
EP2123261A1 (de) 2008-05-20 2009-11-25 Stallergenes S.A. Speichelklebende Partikelformulierung zur Induzierung von antigenspezifischer Immuntoleranz
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
CA2771995C (en) 2008-10-02 2016-11-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Administration of an adborbent polymer for treatment of systemic inflammation
EP2376115A4 (de) 2008-12-11 2013-07-03 Univ Alberta Verfahren und system zur induzierung von immunologischer toleranz bei fremdantigenen
SG193843A1 (en) 2009-01-20 2013-10-30 Univ Northwestern Compositions and methods for induction of antigen-specific tolerance
EP2255831A1 (de) 2009-05-25 2010-12-01 Institut Pasteur Liposom-basierte Diepitop-Konstrukte
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
US20110135744A1 (en) 2009-12-03 2011-06-09 The Regents Of The University Of California Nanoparticle Based Therapy for Dispersing Mucin
US20130209564A1 (en) 2010-02-22 2013-08-15 Shyam M. Rele Polysaccharide Particle Vaccines
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
WO2011133617A1 (en) 2010-04-23 2011-10-27 The Board Of Trustees Of The University Of Illinois Nano-hybrid delivery system for sequential utilization of passive and active targeting
EP2575869B1 (de) 2010-06-04 2017-07-26 Flow Pharma Inc. Peptidpartikelformulierung
JP5703372B2 (ja) 2010-06-04 2015-04-15 トンジ ユニバーシティＴｏｎｇｊｉ Ｕｎｉｖｅｒｓｉｔｙ ピレンおよびピロールのコポリマーならびに該コポリマーの生成方法
CN103068399A (zh) 2010-06-30 2013-04-24 卡姆普根有限公司 用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的c1orf32
US9522183B2 (en) 2010-07-31 2016-12-20 The Scripps Research Institute Compositions and methods for inducing immune tolerance
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
AU2011325966B2 (en) 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
WO2012071014A1 (en) 2010-11-24 2012-05-31 Nanyang Technological University Method for coating particles with calcium phosphate and particles, microparticles and nanoparticles formed thereof
US10064406B2 (en) 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
EP2667843A2 (de) 2011-01-24 2013-12-04 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Nanopartikel auf basis von poly(milchsäureglykol)säure für kosmetische anwendungen
WO2012149393A2 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
WO2013036296A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers
EP2811980A4 (de) 2012-01-31 2015-12-23 Cerulean Pharma Inc Polymerstoffkonjugate, partikel, zusammensetzungen und entsprechende verwendungsverfahren
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
IL292823B2 (en) 2013-03-13 2023-11-01 Cour Pharmaceuticals Dev Company Secondary vaccine particles for the treatment of inflammation
MX2016001931A (es) 2013-08-13 2016-09-07 Univ Northwestern Particulas conjugadas con peptidos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043075A1 (en) * 2002-09-04 2004-03-04 Vladimir Ritter Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Muthu. Asian J Pharm. 2009; 3: 266-273. *
Park. Biomaterials. 1995; 16: 1123-1130. *
Salvadore-Morales et al. Biomaterials. 2009; 30(12): 2231-2240. *
Salvador-Morales et al. Biomaterials. 2009; 30(12): 2231-2240. *
Sampson et al. Ann. N.Y. Acad. Sci.2001; 951: 172-178. *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020424B2 (en) 2010-11-12 2021-06-01 Oncour Pharma, Inc. Modified immune-modulating particles
US10471093B2 (en) 2010-11-12 2019-11-12 Cour Pharmaceuticals Development Company. Modified immune-modulating particles
US11071776B2 (en) 2012-04-23 2021-07-27 N-Fold Llc Nanoparticles for treatment of allergy
US11826407B2 (en) 2012-06-21 2023-11-28 Northwestern University Peptide conjugated particles
US11413337B2 (en) 2012-06-21 2022-08-16 Northwestern University Peptide conjugated particles for the treatment of inflammation
US10201596B2 (en) 2012-06-21 2019-02-12 Northwestern University Peptide conjugated particles for the treatment of allergy
US9913883B2 (en) * 2013-03-13 2018-03-13 Cour Pharmaceuticals Development Company Immune-modifying nanoparticles for the treatment of inflammatory diseases
US20150010631A1 (en) * 2013-03-13 2015-01-08 Cour Pharmaceuticals Development Company Immune-modifying nanoparticles for the treatment of inflammatory diseases
US11045492B2 (en) 2013-03-13 2021-06-29 Oncour Pharma, Inc. Immune-modifying nanoparticles for the treatment of inflammatory diseases
US9999600B2 (en) 2013-04-03 2018-06-19 N-Fold Llc Nanoparticle compositions
US10617747B2 (en) 2013-08-13 2020-04-14 Northwestern University Peptide conjugated particles
US10188711B2 (en) 2013-08-13 2019-01-29 Northwestern University Peptide conjugated particles
US11129881B2 (en) 2013-08-13 2021-09-28 Northwestern University Peptide conjugated particles
US11160851B2 (en) 2013-08-13 2021-11-02 Northwestern University Peptide conjugated particles
US11389517B2 (en) 2013-08-13 2022-07-19 Northwestern University Peptide conjugated particles
US9616113B2 (en) 2013-08-13 2017-04-11 Northwestern University Peptide conjugated particles
US9522180B2 (en) 2013-08-13 2016-12-20 Northwestern University Peptide conjugated particles
WO2019217780A1 (en) 2018-05-11 2019-11-14 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
EP3814272A4 (de) * 2018-05-11 2022-03-02 Phosphorex, Inc. Mikropartikel und nanopartikel mit negativen oberflächenladungen

Also Published As

Publication number Publication date
KR101908445B1 (ko) 2018-10-17
AU2016269431B2 (en) 2019-01-17
KR20180009381A (ko) 2018-01-26
EP2637697A4 (de) 2016-07-13
US20150174155A1 (en) 2015-06-25
US20200030369A1 (en) 2020-01-30
KR101819688B1 (ko) 2018-01-17
AU2011325966A2 (en) 2013-08-01
CN103429232B (zh) 2016-03-16
MX358598B (es) 2018-08-27
US20240245719A1 (en) 2024-07-25
JP5909745B2 (ja) 2016-04-27
CA2817755A1 (en) 2012-05-18
RU2013126725A (ru) 2014-12-20
AU2011325966B2 (en) 2016-09-29
US20200338116A1 (en) 2020-10-29
CA3118108C (en) 2024-02-20
CA2817755C (en) 2021-07-06
KR20140026341A (ko) 2014-03-05
EP2637697A2 (de) 2013-09-18
US11020424B2 (en) 2021-06-01
BR112013011842A2 (pt) 2016-08-16
CN103429232A (zh) 2013-12-04
MX2013005351A (es) 2014-04-14
JP2013545751A (ja) 2013-12-26
AU2016269431A1 (en) 2016-12-22
CA3118108A1 (en) 2012-05-18
WO2012065153A3 (en) 2013-04-25
US10471093B2 (en) 2019-11-12
US20190099443A1 (en) 2019-04-04
AU2011325966A1 (en) 2013-07-04
WO2012065153A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
US20240245719A1 (en) Modified immune-modulating particles
US20240082371A1 (en) Peptide conjugated particles
JP2022184935A (ja) 炎症の治療のための免疫修飾粒子
WO2016057909A1 (en) Immune-modifying particles for the treatment of ebola virus
RU2587853C2 (ru) Модифицированные иммуномодулирующие частицы

Legal Events

Date Code Title Description
AS Assignment

Owner name: GETTS CONSULTING AND PROJECT MANAGEMENT, MICHIGAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GETTS, DANIEL;TERRY, RACHAEL;KING, NICHOLAS;SIGNING DATES FROM 20110503 TO 20120421;REEL/FRAME:028449/0416

AS Assignment

Owner name: GETTS CONSULTING AND PROJECT MANAGEMENT, MICHIGAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GETTS, DANIEL;TERRY, RACHEL;KING, NICHOLAS;SIGNING DATES FROM 20110503 TO 20120421;REEL/FRAME:030886/0018

AS Assignment

Owner name: COUR PHARMACEUTICALS DEVELOPMENT COMPANY, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GETTS CONSULTING AND PROJECT MANAGEMENT;REEL/FRAME:035092/0859

Effective date: 20150120

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ONCOUR PHARMA, INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COUR PHARMACEUTICALS DEVELOPMENT CO., INC.;REEL/FRAME:053847/0736

Effective date: 20200717

AS Assignment

Owner name: COUR PHARMACEUTICALS DEVELOPMENT CO., INC., ILLINOIS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 35092 FRAME: 859. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:GETTS CONSULTING AND PROJECT MANAGEMENT;REEL/FRAME:055621/0683

Effective date: 20150120